Executive Assistant
NewLimit
Executive Assistant
NewLimit
Develops epigenetic medicines to extend healthspan
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat aging by reprogramming the epigenome, a new therapeutic mechanism to restore youthful function in aged cells. We’ve built the world’s leading experimental and artificial intelligence system to discover reprogramming medicines at massive scale. Our first products are focused on restoring youthful metabolic, endothelial, and immune function.
NewLimit is seeking an executive assistant to provide administrative support to the CEO and executive team. This role will be fast-paced and provide you the rare opportunity to help build and scale a leading technology company. You’ll have the opportunity to support the CEO & executive team across all areas of the business, learning what’s required to grow a company in a deep scientific domain.
As a member of our team, you will:
Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Explore more opportunities at NewLimit